RxDoctor Payments Data

David Marks, MD

Interventional Cardiology · Milwaukee, WINPI 1164460010

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,285 of the $10,344 with a category attached, or 99.4%. Abbott accounts for 99.4% of it on its own, with 3 other manufacturers making up the rest.

$10,344in general payments, 2019–2025

Across 20 payments — averaging $517.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$10K
  • Heartflow, Inc.$24
  • Regeneron Healthcare Solutions, Inc.$19
  • Teleflex LLC$16
$38,757in research payments, 2019–2025

Across 9 payments — averaging $4306.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GE HealthCare$25K
  • Abbott$10K
  • W. L. Gore & Associates, Inc.$4K

What the payments were for

  • Consulting fees$10,28599%
  • Food & beverage$591%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,344 in reported general payments places this provider in the 70th percentile of 118 interventional cardiology providers in Wisconsin.

See all interventional cardiology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$29,045
Medicare patients
149
Services billed
296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan32$53,967
JardianceEmpagliflozin18$25,948
EliquisApixaban20$24,181
Praluent PenAlirocumab20$22,632
FarxigaDapagliflozin Propanediol14$16,647
BrilintaTicagrelor13$15,789
Atorvastatin Calcium188$1,678
Metoprolol Succinate115$1,669
Rosuvastatin Calcium93$1,023
Isosorbide Mononitrate ErIsosorbide Mononitrate24$883
Losartan Potassium75$861
Nitroglycerin24$677
Ezetimibe42$589
Carvedilol37$426
Metoprolol Tartrate31$380

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →